The Impact of Prostate Imaging Reporting and Data System Version 2.1 and Prostate-Specific Antigen Density in the Prediction of Clinically Significant Prostate Cancer

Objective: The aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate cancer and to determine whether applying Prostate Imaging Reporting and Data Systems version 2.1 score could improve the diagnostic pathway be...

Full description

Saved in:
Bibliographic Details
Published in:Urology research and practice Vol. 49; no. 2; pp. 120 - 124
Main Authors: Tezcan, Sehnaz, Funda Ulu Ozturk, Bekar, Ulku, Ozturk, Erdem
Format: Journal Article
Language:English
Published: Istanbul Aves Yayincilik Ltd. STI 01.03.2023
Turkish Association of Urology
Subjects:
ISSN:2980-1478, 2980-1478
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Objective: The aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate cancer and to determine whether applying Prostate Imaging Reporting and Data Systems version 2.1 score could improve the diagnostic pathway besides the biochemical characteristics. Materials and methods: In this study, 199 patients with clinically suspected prostate cancer who underwent multiparametric magnetic resonance imaging were included. Logistic regression analyses and receiver operating characteristic curve were performed to determine independent predictors and to compare diagnostic performance of indicators for clinically significant prostate cancer. Two models were established. In model 1, the diagnostic performance of prostate-specific antigen- and prostatespecific antigen density-derived parameters were evaluated. In model 2, the prediction potential of model 1 plus Prostate Imaging Reporting and Data Systems version 2.1 score was analyzed. Results: Sixty-four patients were positive for clinically significant prostate cancer by histopathological analysis (32.1%). In model 1, a prostate-specific antigen density >0.15 was labeled as the strongest predictor of malignancy. In model 2, a prostatespecific antigen density >0.15, a Prostate Imaging Reporting and Data Systems score ≥3, and a Prostate Imaging Reporting and Data Systems score ≥4 demonstrated the strongest association with malignancy. Among these parameters, a Prostate Imaging Reporting and Data Systems score ≥4 (P=.003) was found to be the most robust predictor for malignancy, followed by a Prostate Imaging Reporting and Data Systems score ≥3 (P=.012). The multivariate analysis revealed higher accuracy in model 2 (76.9%) than in model 1 (67.8%). The area under curve values with respect to prostatespecific antigen, prostate-specific antigen density, model 1, and model 2 were 0.632, 0.741, 0.656, and 0.798, respectively. Conclusion: These results indicated that Prostate Imaging Reporting and Data Systems version 2.1 score and prostate-specific antigen density are independent predictors for the presence of clinically significant prostate cancer. Both prostate-specific antigen density and Prostate Imaging Reporting and Data Systems version 2.1 score should be risen to prominence in the decision of biopsy instead of PSA.
AbstractList Objective: The aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate cancer and to determine whether applying Prostate Imaging Reporting and Data Systems version 2.1 score could improve the diagnostic pathway besides the biochemical characteristics. Materials and methods: In this study, 199 patients with clinically suspected prostate cancer who underwent multiparametric magnetic resonance imaging were included. Logistic regression analyses and receiver operating characteristic curve were performed to determine independent predictors and to compare diagnostic performance of indicators for clinically significant prostate cancer. Two models were established. In model 1, the diagnostic performance of prostate-specific antigen- and prostatespecific antigen density-derived parameters were evaluated. In model 2, the prediction potential of model 1 plus Prostate Imaging Reporting and Data Systems version 2.1 score was analyzed. Results: Sixty-four patients were positive for clinically significant prostate cancer by histopathological analysis (32.1%). In model 1, a prostate-specific antigen density >0.15 was labeled as the strongest predictor of malignancy. In model 2, a prostatespecific antigen density >0.15, a Prostate Imaging Reporting and Data Systems score ≥3, and a Prostate Imaging Reporting and Data Systems score ≥4 demonstrated the strongest association with malignancy. Among these parameters, a Prostate Imaging Reporting and Data Systems score ≥4 (P=.003) was found to be the most robust predictor for malignancy, followed by a Prostate Imaging Reporting and Data Systems score ≥3 (P=.012). The multivariate analysis revealed higher accuracy in model 2 (76.9%) than in model 1 (67.8%). The area under curve values with respect to prostatespecific antigen, prostate-specific antigen density, model 1, and model 2 were 0.632, 0.741, 0.656, and 0.798, respectively. Conclusion: These results indicated that Prostate Imaging Reporting and Data Systems version 2.1 score and prostate-specific antigen density are independent predictors for the presence of clinically significant prostate cancer. Both prostate-specific antigen density and Prostate Imaging Reporting and Data Systems version 2.1 score should be risen to prominence in the decision of biopsy instead of PSA.
The aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate cancer and to determine whether applying Prostate Imaging Reporting and Data Systems version 2.1 score could improve the diagnostic pathway besides the biochemical characteristics.OBJECTIVEThe aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate cancer and to determine whether applying Prostate Imaging Reporting and Data Systems version 2.1 score could improve the diagnostic pathway besides the biochemical characteristics.In this study, 199 patients with clinically suspected prostate cancer who underwent multiparametric magnetic resonance imaging were included. Logistic regression analyses and receiver operating characteristic curve were performed to determine independent predictors and to compare diagnostic performance of indicators for clinically significant prostate cancer. Two models were established. In model 1, the diagnostic performance of prostate-specific antigen- and prostatespecific antigen density-derived parameters were evaluated. In model 2, the prediction potential of model 1 plus Prostate Imaging Reporting and Data Systems version 2.1 score was analyzed.MATERIALS AND METHODSIn this study, 199 patients with clinically suspected prostate cancer who underwent multiparametric magnetic resonance imaging were included. Logistic regression analyses and receiver operating characteristic curve were performed to determine independent predictors and to compare diagnostic performance of indicators for clinically significant prostate cancer. Two models were established. In model 1, the diagnostic performance of prostate-specific antigen- and prostatespecific antigen density-derived parameters were evaluated. In model 2, the prediction potential of model 1 plus Prostate Imaging Reporting and Data Systems version 2.1 score was analyzed.Sixty-four patients were positive for clinically significant prostate cancer by histopathological analysis (32.1%). In model 1, a prostate-specific antigen density >0.15 was labeled as the strongest predictor of malignancy. In model 2, a prostatespecific antigen density >0.15, a Prostate Imaging Reporting and Data Systems score ≥3, and a Prostate Imaging Reporting and Data Systems score ≥4 demonstrated the strongest association with malignancy. Among these parameters, a Prostate Imaging Reporting and Data Systems score ≥4 (P=.003) was found to be the most robust predictor for malignancy, followed by a Prostate Imaging Reporting and Data Systems score ≥3 (P=.012). The multivariate analysis revealed higher accuracy in model 2 (76.9%) than in model 1 (67.8%). The area under curve values with respect to prostatespecific antigen, prostate-specific antigen density, model 1, and model 2 were 0.632, 0.741, 0.656, and 0.798, respectively.RESULTSSixty-four patients were positive for clinically significant prostate cancer by histopathological analysis (32.1%). In model 1, a prostate-specific antigen density >0.15 was labeled as the strongest predictor of malignancy. In model 2, a prostatespecific antigen density >0.15, a Prostate Imaging Reporting and Data Systems score ≥3, and a Prostate Imaging Reporting and Data Systems score ≥4 demonstrated the strongest association with malignancy. Among these parameters, a Prostate Imaging Reporting and Data Systems score ≥4 (P=.003) was found to be the most robust predictor for malignancy, followed by a Prostate Imaging Reporting and Data Systems score ≥3 (P=.012). The multivariate analysis revealed higher accuracy in model 2 (76.9%) than in model 1 (67.8%). The area under curve values with respect to prostatespecific antigen, prostate-specific antigen density, model 1, and model 2 were 0.632, 0.741, 0.656, and 0.798, respectively.These results indicated that Prostate Imaging Reporting and Data Systems version 2.1 score and prostate-specific antigen density are independent predictors for the presence of clinically significant prostate cancer. Both prostate-specific antigen density and Prostate Imaging Reporting and Data Systems version 2.1 score should be risen to prominence in the decision of biopsy instead of PSA.CONCLUSIONThese results indicated that Prostate Imaging Reporting and Data Systems version 2.1 score and prostate-specific antigen density are independent predictors for the presence of clinically significant prostate cancer. Both prostate-specific antigen density and Prostate Imaging Reporting and Data Systems version 2.1 score should be risen to prominence in the decision of biopsy instead of PSA.
Author Funda Ulu Ozturk
Ozturk, Erdem
Bekar, Ulku
Tezcan, Sehnaz
Author_xml – sequence: 1
  givenname: Sehnaz
  surname: Tezcan
  fullname: Tezcan, Sehnaz
– sequence: 2
  fullname: Funda Ulu Ozturk
– sequence: 3
  givenname: Ulku
  surname: Bekar
  fullname: Bekar, Ulku
– sequence: 4
  givenname: Erdem
  surname: Ozturk
  fullname: Ozturk, Erdem
BookMark eNpdUEtv1DAQtlCRKKVnrpa4cMliO3Fin1C1LVCpEhVbuEbeyWzqKhkH20HaP8TvJIEiHqcZzfeamefshAIhYy-l2Gip1Zs8dxslVLlRSkhrn7BTZY0oZNWYk7_6Z-w8pQchhDKNsqI5Zd_v7pFfj5ODzMOB38aQssvryPWeev4JpxDz2jnq-KXLju-OKePIv2BMPhBXG_kT-y0tdhOCP3jgF5R9j8QvkZLPR-6J5yXtNmLnIa_aJXE7ePLghuHId76nVego_1lk6wgwvmBPD25IeP5Yz9jnd1d32w_Fzcf319uLmwJKa3PRQGfAgAWpdS1kJfa6qhq0rgMJJTZ1Ja2WrpZd1e0F7ms8KKmlcDWgLA2UZ-ztL99p3o_YAVKObmin6EcXj21wvv0XIX_f9uFbK5e3q8boxeH1o0MMX2dMuR19AhwGRxjm1CpjZLOyy4X66j_qQ5gjLfctLFEbKWotyh_X3ZeB
CitedBy_id crossref_primary_10_3389_fonc_2024_1467793
ContentType Journal Article
Copyright 2023. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://turkishjournalofurology.com/en/copyright-1011
2023 authors 2023 authors
Copyright_xml – notice: 2023. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://turkishjournalofurology.com/en/copyright-1011
– notice: 2023 authors 2023 authors
DBID 3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
EDSIH
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.5152/tud.2023.220199
DatabaseName ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central
ProQuest One Community College
ProQuest Central
Turkey Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Turkey Database
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2980-1478
EndPage 124
ExternalDocumentID PMC10192785
GroupedDBID 3V.
7X7
7XB
8FI
8FJ
8FK
ABDBF
ABUWG
AFFHD
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
CCPQU
DWQXO
EDSIH
EOJEC
ESX
FYUFA
GROUPED_DOAJ
HMCUK
K9.
OBODZ
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
RPM
TUS
UKHRP
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c399t-7cd8c8c9c15560140b5447e9adc1c3e7641951a61d4db0eb6ef21510a6ce138c3
IEDL.DBID 7X7
ISICitedReferencesCount 1
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001002995800008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2980-1478
IngestDate Tue Nov 04 02:07:38 EST 2025
Thu Sep 04 18:45:00 EDT 2025
Sat Nov 29 14:26:11 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
License Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c399t-7cd8c8c9c15560140b5447e9adc1c3e7641951a61d4db0eb6ef21510a6ce138c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Cite this article as: Tezcan S, Ulu Ozturk F, Bekar U, Ozturk E. The impact of prostate imaging reporting and data system version 2.1 and prostate-specific antigen density in the prediction of clinically significant prostate cancer. Urol Res Pract., 2023;49(2):120-124.
ORCID 0000-0001-7204-3008
0000-0003-2782-2824
0000-0001-6963-2880
0000-0002-2360-788X
OpenAccessLink https://www.proquest.com/docview/2806810650?pq-origsite=%requestingapplication%
PQID 2806810650
PQPubID 106063
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10192785
proquest_miscellaneous_2881710193
proquest_journals_2806810650
PublicationCentury 2000
PublicationDate 2023-03-01
PublicationDateYYYYMMDD 2023-03-01
PublicationDate_xml – month: 03
  year: 2023
  text: 2023-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Istanbul
PublicationPlace_xml – name: Istanbul
PublicationTitle Urology research and practice
PublicationYear 2023
Publisher Aves Yayincilik Ltd. STI
Turkish Association of Urology
Publisher_xml – name: Aves Yayincilik Ltd. STI
– name: Turkish Association of Urology
SSID ssj0002872907
Score 2.2189739
Snippet Objective: The aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate...
The aim of this study was to evaluate the diagnostic performance of multiparametric magnetic resonance imaging for clinically significant prostate cancer and...
SourceID pubmedcentral
proquest
SourceType Open Access Repository
Aggregation Database
StartPage 120
SubjectTerms Antigens
Clinical significance
Magnetic resonance imaging
Original
Prostate cancer
Urology
Urooncology
Title The Impact of Prostate Imaging Reporting and Data System Version 2.1 and Prostate-Specific Antigen Density in the Prediction of Clinically Significant Prostate Cancer
URI https://www.proquest.com/docview/2806810650
https://www.proquest.com/docview/2881710193
https://pubmed.ncbi.nlm.nih.gov/PMC10192785
Volume 49
WOSCitedRecordID wos001002995800008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2980-1478
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002872907
  issn: 2980-1478
  databaseCode: DOA
  dateStart: 20220101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: AUTh Library subscriptions: ProQuest Central
  customDbUrl:
  eissn: 2980-1478
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002872907
  issn: 2980-1478
  databaseCode: BENPR
  dateStart: 20090301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2980-1478
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002872907
  issn: 2980-1478
  databaseCode: 7X7
  dateStart: 20090301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2980-1478
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002872907
  issn: 2980-1478
  databaseCode: PIMPY
  dateStart: 20090301
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Turkey Database
  customDbUrl:
  eissn: 2980-1478
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0002872907
  issn: 2980-1478
  databaseCode: EDSIH
  dateStart: 20090301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/turkey
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NT8MgFCe6efDiR9Q4nQsmXlHpOqAnMzeNHlwaP5J5WoAybWI63TqT_UP-nb5HO-cuXrw0bYFA4MH7PXj8HiEnkTBOtqxgXAvLQqU5iwBmsIAbaa0IW04rH2xC9nqq34_icsNtUrpVztdEv1AnI4t75Gd4Aqg4AoqL9w-GUaPwdLUMobFKqhg2G-Vc9uXPHgtYAwEYfwWjDyju4CyfIjto0DwNQPFFy7By2Snyl5a53vxv-7bIRokvabsQiG2yko93yBcIA7319yHpaEhjvOkBGBN--RhFtEDh-KazhHZ1rmnBZE7L7TQanHKfNi_KfNz6YWppO8uR0JN20RM-n9E0o4ApISOeAOGoY40l--jb24w-pC8ZFoQRXTSkg7I33iVP11ePnRtWBmhgFnBNziQSCygbWQAlAk010wpD6SKdWG6bToqQA4DTgidhYs6dEW6ICOMcxMLxprLNPVLJRpnbJ3QIMNJo45xVYOIFIgJc5ERojUEN6lyN1OfdPihn2WSw6PMaOf5JhvmBhx46c6Mp5lEcUBTg1BpRSyM8eC_4PAbIsL2ckqWvnmkbywVStQ7-rv2QrKNQFa5pdVLJx1N3RNbsZ55Oxg0vk_6pGqR6edWL7xve9Iev-PYufv4GKez2Iw
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VgkQvPASIQAtGgqPb2tnY3gOqqoaqUUtUqUXKbbG9Exqp2oRkA8of4shvZGYfLblw64Hbam3vwx7PfON5AbxPTUDbi0Yqb6JMnFcyJZghtQo2RpP00Luq2IQdDt1olJ5vwO82FobdKlueWDHqfBr5jHyPLYBOMaA4mH2XXDWKrattCY2aLE5x9ZNUtsXHQZ_W94PWx58uj05kU1VARhLGpbQcDe9iGkmSGtYvQi9JLKY-jyp20ZpEEerwRuVJHvYxGByzWNynf0HVdbFLz70H94mPW1b27MjenOmQ9qFJ2awzCBFQ0HvlkrOR6u6uJkGbrsPYdSfMv6Ta8eP_bT6ewKMGP4vDmuCfwkY5fwa_iNjFoIr3FNOxOOdIFsLQdKuqwSRqLYOvfJGLvi-9qDO1i-a4UOhdVbW1Q-XFDCtvRXFYlJywVPTZ079ciUkhCDNTR7ZwMVXzG5vsqtfXK3Ex-VbwQKLY2w854r01fw5f7mRqXsBmMS3wJYgxweTgA2J0pMJqkxLuQ5PEEBghIHZgu13mrOEii-x2jTvw7qaZ9j8bdXyB0yX3cYpQIuHwDrg1ispmdb6SjDOIr7cUk6sqkziP09b1Xv377W_h4cnl57PsbDA8fQ1bTNC1G942bJbzJe7Ag_ijnCzmb6r9IODrXRPcH4rCTZM
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VFCEuPASogUKNBEc3tbPxeg8IVQ0RUSFaqSCV02J7JxCp2oRkA8of4kfw65jZR9tcuPXAbbW292HPeL7xvABeJcZjPAhGKmeCjKxTMiGYIbXycQgmGqCzVbGJeDKx5-dJugN_2lgYdqts98Rqo87ngc_Ie2wBtIoBRW_auEWkw9HbxQ_JFaTY0tqW06hJ5BQ3v0h9W70ZD2mtX2s9evfp5L1sKgzIQIK5lDFHxtuQBJKqhnUNP4iiGBOXBxX6GJtIEQJxRuVR7o_QG5yyiDyi_0LVt6FPz70FuwTJI92B3XT8Mf1yecJDuogm1bPOJ0SwQffKNecm1f1DTWI32Qa12y6Z12Tc6P7_PDsP4F6DrMVxzQoPYadcPoLfxAZiXEWCivlUpBzjQuiablXVmUStf_CVK3IxdKUTdQ530RwkCn2oqrZ2qDxbYOXHKI6LklOZiiHHAJQbMSsEoWnqyLYvpnd-Y5N39eJiI85m3woeSLR89SEnzHXLx_D5RqbmCXSKeYF7IKYEoL3ziMGScqtNQogQTRS8Z-yA2IX9dsmzZn9ZZVfr3YWXl820M7C5xxU4X3Mfqwg_EkLvgt2irmxRZzLJOLf4dksx-17lGOdxOraDp_9--wHcITrLPownp8_gLtN27Z-3D51yucbncDv8LGer5YuGOQR8vWmK-wuD2lfi
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Impact+of+Prostate+Imaging+Reporting+and+Data+System+Version+2.1+and+Prostate-Specific+Antigen+Density+in+the+Prediction+of+Clinically+Significant+Prostate+Cancer&rft.jtitle=Urology+research+and+practice&rft.au=Tezcan%2C+Sehnaz&rft.au=Funda+Ulu+Ozturk&rft.au=Bekar%2C+Ulku&rft.au=Ozturk%2C+Erdem&rft.date=2023-03-01&rft.pub=Aves+Yayincilik+Ltd.+STI&rft.eissn=2980-1478&rft.volume=49&rft.issue=2&rft.spage=120&rft_id=info:doi/10.5152%2Ftud.2023.220199&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2980-1478&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2980-1478&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2980-1478&client=summon